Key takeaways: METiS Pharmaceuticals has completed five funding rounds since its establishment in January 2020, including the latest two worth $150 million The company was incubated by AI pharmaceutical unicorn XtaiPl, whose most recent valuation exceeded $2. Read more: https://www.benzinga.com/news/22/04/26596254/ai-pharma-startup-metis-raises-150-million-ipo-in-sight
We also support Hindi language, do you want change to it? We also support Punjabi language, do you want change to it? Read more: https://bit.ly/3xDZGfN
Are you a parent with kids in school or doing remote learning? Or a teacher back in the classroom or working on Zoom? We want to hear your stories about educating kids in the time of Covid-19 for an upcoming… Continue Reading →
Cancer sucks, but there are some exciting developments on the research front. In the last month alone, we’ve seen regulators consider a CRISPR therapy that directly targets tumor cells—a first for the U.S. Read more: http://bit.ly/2RereTX
明報記者 陳惠恩 內地去年限制走資，影響上市公司的估值水平，生物科技股亦同受影響。夏爾巴投資創始人及管理合伙人蔡大慶表示，目前資金流向稍為偏穩，但市場仍盼望有較明顯的放開資金限制。他認為，估值對生物科技 Read more: http://bit.ly/2wzXibn
原文刊於信報財經新聞專欄「StartupBeat創科鬥室」 Evivo入門套裝足夠嬰兒服用4周，售價由638港元起。（Evivo網上圖片） 美國生物科技公司Evolve BioSystems周一（6日）宣布，在香港和新加坡等市場，推出其嬰幼兒益生菌產品Evivo。 Read more: http://bit.ly/2YJPlfR
股債回報快，有本港「賓架」5年前卻毅然轉型，開創回報無期的生物科技集團。他直認是受清太宗皇太極影響，相信孫子兵法「不硬撼」為王道，有見美國生物科技市場競爭激烈，選擇開拓香港和英聯邦的新興市場，冀把握本 Read more: http://bit.ly/2oOXj7R
© 2024 尹思哲 — Powered by WordPress
Theme by Anders Noren — Up ↑